CD19-specific chimeric antigen receptor T-cell therapy (CD19 CART) has demonstrated significant improvements in overall response rates (ORRs) and complete response rates (CRRs) for patients with relapsed/refractory aggressive B-cell lymphoma (r/r aBCL), with reported rates ranging from 52.0% to 83% (1–4). This evidence concerns the gene CD19 and B-cell non-Hodgkin lymphoma.